TITLE

Research Capsules

PUB. DATE
June 2005
SOURCE
Pharmaceutical Representative;Jun2005, Vol. 35 Issue 6, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information related to drug development in the U.S. First year results of the two-year, double-blind, phase III RIO-Europe trial published in the journal "The Lancet" suggest that treatment with Bridgewater, New Jersey-based Sanofi-Aventis SA's Acomplia or rimonabant may significantly decrease body weight and improve cardiovascular risk factors in overweight or obese individuals. Adding South San Francisco, California-based Genentech Inc.'s Herceptin or trastuzumab to chemotherapy may significantly increase the rate of pathologic complete response in patients with operable human epidermal growth factor receptor 2-positive breast cancer, according to research published in the "Journal of Clinical Oncology."
ACCESSION #
17482093

 

Related Articles

  • CLINICAL TRIALS NEWS.  // Applied Clinical Trials;Apr2005, Vol. 14 Issue 4, p18 

    Reports global developments on clinical trials of investigational drugs by different pharmaceutical companies. Potential therapeutic value of Abbott Laboratories Inc.'s Humira (adalimumab) for patients with Crohn's disease who stopped responding to Remicade (infliximab); Indications showing that...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p4 

    The article reports developments related to antineoplastic agents industry in the U.S. Genentech Inc. has proven its Avastin as effective therapy to improve the survival in colorectal cancer patients in a combination regime. Sanofi-Aventis SA has received marketing approval from the Food and...

  • Resistance to HER2-Targeted Therapy in HER2+ Breast Cancer. Kessler, Elizabeth R.; Elias, Anthony D. // Clinical Medicine Reviews in Women's Health;2012, Issue 4, p15 

    Breast cancer is the most commonly diagnosed cancer in women and one of the earliest tumor types for which we have used molecular characterization of the tumor to guide treatment. Approximately one quarter of breast tumors show overexpression of HER2, a transmembrane receptor tyrosine kinase....

  • Early Stage p53 Program Lands Ascenta $398M Deal with Sanofi. Boggs, Jennifer // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p1 

    The article reports on the partnership for an early stage cancer program between Ascenta Therapeutics Inc. and Sanofi-Aventis SA. Under the partnership, licensed products to be developed will be targeting the p53 protein, a tumor suppressor gene. Ascenta can earn up to 398 million dollars from...

  • Docetaxel gets nod for stomach cancer.  // Drug Topics;4/17/2006, Vol. 150 Issue 8, p12 

    The article focuses on the use of docetaxel (Taxotere, Sanofi-Aventis) in mixture with cisplatin and 5-fluorouracil (5-FU) in reducing the mortality rate of patients that at one time has advanced stomach cancer as opposed to patients getting only cisplatin and 5-FU. The U.S. Food and Drug...

  • Genentech: Omnitarg failure takes gloss off pipeline.  // PharmaWatch: Monthly Review;Jul2005, Vol. 4 Issue 7, p7 

    The article reports on the results of phase II clinical trial of Genentech Inc.'s cancer antibody Omnitarg in the U.S. Indications show that its humanized monoclonal antibody product Omnitarg had limited activity when used as a monotherapy to treat ovarian, breast and prostate cancers. The poor...

  • Genentech Buyout Price Looking Better on Avastin Adjuvant Miss. Boggs, Jennifer // BioWorld Today;4/23/2009, Vol. 20 Issue 77, p1 

    The article focuses on the adjuvant data from Genentech Inc.'s study which showed that its blockbuster cancer drug Avastin failed to improve disease-free survival in early-stage colon cancer patients when added to chemotherapy. The study was designed to test the drug in combination with FOLFOX...

  • Call the Shot. PARKHURST, ERIN // Virginia Living;Dec2015, Vol. 14 Issue 1, p103 

    The article evaluates the Praluent, an inhibitor monoclonal antibody, developed by Sanofi Aventis U.S. and Regeneron Pharmaceuticals Inc.

  • BIOLOGY -- PROGNOSTIC FACTORS.  // Current Medical Literature: Breast Cancer;2005, Vol. 17 Issue 3, p61 

    Discusses several studies on the prognostic factors of breast cancer published in the 2005 issue of the "Journal of Clinical Oncology." Validation of the prognostic model Adjuvant for early breast cancer; Ways to improve the survival prospects of breast cancer patients; Risks associated with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics